Categories: aggregated

Patient Zero for Untreatable Depression Begins Groundbreaking Psychedelics Therapy – Ending Depression Through Psilocybin?

In a phase 2b clinical trial, Beckley Psytech has started treating the first subject for BPL-003, an intranasal synthetic formulation of the psychedelic chemical 5-MeO-DMT intended for patients with treatment-resistant depression. With FDA clearance for investigational new medication status in February, this groundbreaking research represents the biggest controlled examination into the potential of 5-MeO-DMT, involving 40 locations throughout Australia, Europe, and the US.

Jason

Share
Published by
Jason

Recent Posts

Former New York Knick Iman Shumpert debuts legal cannabis brand with Glenmere Farms

The NBA champion and New York Knick will premier his new flower brand at Torches…

2 days ago

How New York pot pioneers made it to legal dispensary shelves

By: LMC Legacy to licensed is the motto for authentic New York brands entering the…

2 days ago

Vladimir Bautista is leading Happy Munkey’s legacy-to-legal takeover

Vlad Bautista began his cannabis empire in Harlem's Sugar Hill. Nearly 30 years later, his…

2 days ago

Scientists Now Think That One Compound in the Cannabis Plant Can Replace All Opiates

Cannabis terpenes are the compounds responsible for the aromatic profile of each strain; they are…

2 days ago

Cannabis and the Authoritarian State – Why Legalizing Cannabis Is Not on the Horizon

Authoritarians cannot let go of the value that keeping the most widely used illicit substance…

3 days ago